BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35113257)

  • 1. Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients.
    Lin PH; Chen SC; Tseng LM; Chang KJ; Huang AC; Cheng KC; Yang K; Wu HC; Chao TY; Chang YC; Lin PC; Kuo WH; Kuo WL; Lin CH; Chen HM; Yeh DC; Liu LC; Liu CY; Wang MY; Lo C; Lu YS; Huang CS
    Breast Cancer Res Treat; 2022 Apr; 192(3):629-637. PubMed ID: 35113257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
    Ryu JM; Choi HJ; Kim I; Nam SJ; Kim SW; Yu J; Lee SK; Choi DH; Park YH; Kim JW; Seo JS; Park JH; Lee JE; Kim SW;
    Breast Cancer Res Treat; 2019 Jan; 173(2):385-395. PubMed ID: 30350268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
    Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation.
    Ye F; Huang L; Lang G; Hu X; Di G; Shao Z; Cao A
    Cancer Med; 2020 Mar; 9(5):1903-1910. PubMed ID: 31912664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.
    Pellegrino B; Bella M; Michiara M; Zanelli P; Naldi N; Porzio R; Bortesi B; Boggiani D; Zanoni D; Camisa R; Neri TM; Pinto C; Musolino A
    Acta Biomed; 2016 May; 87(1):54-63. PubMed ID: 27163896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
    De Talhouet S; Peron J; Vuilleumier A; Friedlaender A; Viassolo V; Ayme A; Bodmer A; Treilleux I; Lang N; Tille JC; Chappuis PO; Buisson A; Giraud S; Lasset C; Bonadona V; Trédan O; Labidi-Galy SI
    Sci Rep; 2020 Apr; 10(1):7073. PubMed ID: 32341426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
    Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
    Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
    Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
    Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
    Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
    Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
    Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
    Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for
    Sun J; Chu F; Pan J; Zhang Y; Yao L; Chen J; Hu L; Zhang J; Xu Y; Wang X; Cao W; Xie Y
    J Clin Oncol; 2023 Feb; 41(5):991-999. PubMed ID: 36480783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer treatment in mutation carriers: surgical treatment.
    Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
    Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.
    Yadav S; Ladkany R; Yadav D; Alhalabi O; Khaddam S; Isaac D; Cardenas PY; Zakalik D
    Clin Breast Cancer; 2018 Oct; 18(5):e1229-e1235. PubMed ID: 29402697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
    JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
    Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
    Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.
    Akkoc Mustafayev FN; Shukla MA; Lanier A; Milton DR; Gutierrez AM; Gruschkus SK; Lewis JE; Murthy RK; Arun BK
    Cancer; 2024 May; 130(9):1600-1608. PubMed ID: 38100492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.